Rigel Pharmaceuticals has lived up to its name. The group, which owes its title to the brightest star in the Orion constellation, yesterday put in a stellar performance and tripled its share price on the back of positive phase II data for its rheumatoid arthritis drug.A study of 189 patients showed that R788 significantly alleviated symptoms of rheumatoid arthritis (RA). This caused the shares to rocket from $8 to $25.95. Today, they continued their upward trajectory and rose a further 10% in early trading to $28.50.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.